C07D231/50

Pyrazole derivatives useful as 5-lipdxygenase activating protein (FLAP) inhibitors

The present application relates to novel compounds of formula (I) ##STR00001##
to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.

CRYSTALLINE FORM OF (1R,2R)-2-[4-(3-METHY1-1H-PYRAZOL-5-YL)BENZOYL]-N-(4-OXO-4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZIN-3-YL)CYCLOHEXANECARBOXAMIDE
20190276460 · 2019-09-12 · ·

A crystalline form of (1R,2R)-2-[4-(3-Methyl-1H-pyrazol-5-yl)benzoyl]-N-(4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)cyclohexanecarboxamide, pharmaceutical compositions containing it and its use in therapy.

Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors

The present application relates to novel compounds of formula (I) ##STR00001##
to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.

Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors

The present application relates to novel compounds of formula (I) ##STR00001##
to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.

PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS

The present application relates to novel compounds of formula (I)

##STR00001##

to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.

PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS

The present application relates to novel compounds of formula (I)

##STR00001##

to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.

Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors

The present application relates to novel compounds of formula (I) ##STR00001##
to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.

Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors

The present application relates to novel compounds of formula (I) ##STR00001##
to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.

PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS

The present application relates to novel compounds of formula (I)

##STR00001##

to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.

PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS

The present application relates to novel compounds of formula (I)

##STR00001##

to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.